Major adverse events associated with lipid reduction in inclisiran: a pharmacovigilance research of the FAERS database
Inclisiran has good long-term treatment outcomes and safety. However, attention should be paid to adverse events with high-risk signals.
Authors
- Yu Duan (ORCID: https://orcid.org/0000-0002-2994-7623)
- D. Wang (ORCID: https://orcid.org/0000-0002-1309-8946)
- Wenhui Zhang (ORCID: https://orcid.org/0000-0001-9673-1999)
- Xinyang He
- Xu Qian (ORCID: https://orcid.org/0000-0001-5539-1983)
- Zitong Huang (ORCID: https://orcid.org/0000-0001-7936-4963)
- Yashan Gao (ORCID: https://orcid.org/0000-0003-4537-6741)
- Z. H. Jia (ORCID: https://orcid.org/0000-0001-8277-8657)
- Yajuan Zhang (ORCID: https://orcid.org/0000-0002-5470-9440)
Institutions
- Chengde Medical University (CN)
- Shandong First Medical University (CN)
Publication Details
- Journal
- Expert Opinion on Drug Safety
- Published
- 2024-12-25
- DOI
- https://doi.org/10.1080/14740338.2024.2446407
- Citations
- 2
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 1.15